@article{e6c4b54c79e744118c86d558085ded71,
title = "One-year effects of omega-3 treatment on fatty acids, oxylipins, and related bioactive lipids and their associations with clinical lipid and inflammatory biomarkers: Findings from a substudy of the vitamin d and omega-3 trial (vital)",
abstract = "Omega-3 (n-3) treatment may lower cardiovascular risk, yet its effects on the circulating lipidome and relation to cardiovascular risk biomarkers are unclear. We hypothesized that n-3 treatment is associated with favorable changes in downstream fatty acids (FAs), oxylipins, bioactive lipids, clinical lipid and inflammatory biomarkers. We examined these VITAL200, a nested substudy of 200 subjects balanced on demographics and treatment and randomly selected from the Vitamin D and Omega-3 Trial (VITAL). VITAL is a randomized double-blind trial of 840 mg/d eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) vs. placebo among 25,871 individuals. Small polar bioactive lipid features, oxylipins and FAs from plasma and red blood cells were measured using three independent assaying techniques at baseline and one year. The Women's Health Study (WHS) was used for replication with dietary n-3 intake. Randomized n-3 treatment led to changes in 143 FAs, oxylipins and bioactive lipids (False Discovery Rate (FDR) < 0.05 in VITAL200, validated (p-values < 0.05)) in WHS with increases in 95 including EPA, DHA, n-3 docosapentaenoic acid (DPA-n3), and decreases in 48 including DPA-n6, dihomo gamma linolenic (DGLA), adrenic and arachidonic acids. N-3 related changes in the bioactive lipidome were heterogeneously associated with changes in clinical lipid and inflammatory biomarkers. N-3 treatment significantly modulates the bioactive lipidome, which may contribute to its clinical benefits.",
keywords = "Bioactive lipids, Clinical trial, Free fatty acids, Inflammatory biomarkers, Lipids, Metabolomics, Omega-3, Oxylipins",
author = "Demler, {Olga V.} and Yanyan Liu and Heike Luttmann-Gibson and Watrous, {Jeramie D.} and Lagerborg, {Kim A.} and Hesam Dashti and Franco Giulianini and Mallory Heath and Camargo, {Carlos A.} and Harris, {William S.} and Wohlgemuth, {Jay G.} and Andres, {Allen M.} and Saumya Tivari and Tao Long and Mahan Najhawan and Khoi Dao and Prentice, {James G.} and Larsen, {Julia A.} and Okereke, {Olivia I.} and Costenbader, {Karen H.} and Buring, {Julie E.} and Manson, {Joann E.} and Susan Cheng and Mohit Jain and Samia Mora",
note = "Funding Information: Conflicts of Interest: O.V.D.: KOWA Pharmaceuticals for work unrelated to the current study; J.G.W.: Quest Diagnostics (data collection); J.G.P.: Quest Diagnostics, Inc. (data collection); J.A.L.: Quest Diagnostics, Inc. (data collection); Consultant: Quest Diagnostics; W.S.H.: OmegaQuant Analytics, LLC; S.C.: Zogenix, Research Grant; NIH; S.M.: investigator initiated research grant from Atherotech Diagnostics, consultant to Quest Diagnostics and Pfizer for work unrelated to the current study. Quest Diagnostics measured the plasma PL and OmegaQuant measured the RBC—both at no additional cost to the study. The funders had no role in the design of the study; in the analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Funding Information: Funding: This project was supported in part by the National Institutes of Health grants: 5K01HL135342 (Olga V. Demler), R01HL134811, R01HL134168 and 1R01HL143227, and K24HL136852, and R01DK112940 (Samia Mora) NIH R01AR059086, NIH R01AR059086, NIH R01MH091448, NIH K01DK116917 (Jeramie D. Watrous), T32 HL007575 (Hesam Dashti) and S10OD020025, R01ES027595, U54AG065141 and R01HL143227 (Mohit Jain and Susan Cheng).Olga V. Demler was additionally supported by the Brigham and Women{\textquoteright}s Hospital Lerner Junior Faculty Research Award. U01 CA138962 and R01 CA138962 (NCI, the NHLBI, the Office of Dietary Supplements, the National Institute of Neurological Disorders and Stroke, and the National Center for Complementary and Integrative Health of the NIH) to VITAL NCT01169259. National Institutes of Health grants CA047988, HL043851, HL080467, HL099355, and UM1CA182913 to Women{\textquoteright}s Health Study. Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2020",
month = nov,
doi = "10.3390/metabo10110431",
language = "English (US)",
volume = "10",
pages = "1--20",
journal = "Metabolites",
issn = "2218-1989",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",
}